TITLE

Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)

PUB. DATE
January 2008
SOURCE
BMC Genetics;2008, Vol. 9, p361
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
43750597

 

Related Articles

  • Failure as a route to success. CHANTRILL, LORRAINE // Australasian Science;Nov2015, Vol. 36 Issue 9, p33 

    The article focuses on the challenges that blocked the development of new treatments for pancreatic cancer. Topics include key characteristic of the cancer that impede the development of new treatments, the IMPaCT randomised clinical trial of genomically guided pancreatic cancer treatment, and...

  • Current status of chemoradiotherapy for locally advanced pancreatic cancer in Japan. Okusaka, Takuji; Ito, Yoshinori; Furuse, Junji; Yamada, Shigeru; Ishii, Hiroshi; Shibuya, Keiko; Ioka, Tatsuya; Shinchi, Hiroyuki // International Journal of Clinical Oncology;Apr2008, Vol. 13 Issue 2, p127 

    Although the results of randomized controlled trials for locally advanced pancreatic cancer conducted between 1969 and 1988 demonstrated a survival advantage for concurrent radiotherapy and bolus 5-fluorouracil (FU) injection, the prognosis of patients with this disease remains very poor. In an...

  • Randomized phase II -- study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer -- PARC: study protocol [ISRCTN56652283]. Krempien, R.; Muenter, M. W.; Huber, P. E.; Nill, S.; Friess, H.; Timke, C.; Didinger, B.; Buechler, P.; S.Heeger; Herfarth, K. K.; Abdollahi, A.; Buchler, M. W.; Debus, J. // BMC Cancer;2005, Vol. 5, p131 

    Background: Pancreatic cancer is the fourth commonest cause of death from cancer in men and women. Advantages in surgical techniques, radiation therapy techniques, chemotherapeutic regimes, and different combined-modality approaches have yielded only a modest impact on the prognosis of patients...

  • BSD Medical study gains attention.  // Medical Device Daily;5/8/2012, Vol. 16 Issue 89, p5 

    The article reports on the results of a phase III clinical study by BSD Medical of hyperthermia in combination with chemotherapy for the treatment of pancreatic cancer patients.

  • Treatment of unresectable pancreatic cancer. Carter, D.C. // British Medical Journal (Clinical Research Edition);6/12/1982, Vol. 284 Issue 6331, p1727 

    Examines the treatment of unresectable pancreatic cancer. Importance of chemotherapy and radiotherapy; Measurement of tumor response; Efficacy of palliative radiotherapy.

  • dying with eyes wide open. Alschuler, Alfred // Art of Healing;Dec2015-Feb2016, Vol. 4 Issue 53, p38 

    The article presents a personal narrative which explores the author's experience of suffering from pancreatic cancer and undergoing chemotherapy and other treatments.

  • Targeted toxins begin to live up to early expectations. Thompson, Tracy; Thompson, T // JNCI: Journal of the National Cancer Institute;5/16/2001, Vol. 93 Issue 10, p736 

    Reports on the developments concerning the clinical trials of targeted toxins to be used for cancer treatment. Comparison of targeted toxins with chemotherapy and radiation; Challenges in designing targeted toxins.

  • Current Status of Adjuvant Therapy for Pancreatic Cancer. KATZ, MATTHEW H. G.; FLEMING, JASON B.; LEE, JEFFREY E.; PISTERS, PETER W. T. // Oncologist;Nov2010, Vol. 15 Issue 11, p1205 

    In this article, we review the rationale for and outcomes associated with the use of adjuvant and neoadjuvant therapy for resectable and borderline resectable cancer of the pancreatic head and uncinate process. Localized pancreatic cancer is a systemic disease that requires nonoperative...

  • Opinion: Rethinking clinical trials for cytostatic drugs. Millar, Andrew W.; Lynch, Kevin P. // Nature Reviews Cancer;Jul2003, Vol. 3 Issue 7, p540 

    The failure of many cytostatic agents in Phase III clinical trials for treatment of common cancers has led researchers to question current approaches to trial development. Recent studies offer some clues as to what is wrong with two particular aspects of clinical trial design - survival as an...

  • Significance of Targeting NF-κB Activation in Novel Therapeutic Strategies for Advanced Pancreatic Cancer. Uwagawa, Tadashi; Yanaga, Katsuhiko // Asia Pacific Journal of Oncology & Hematology;2009, Vol. 1 Issue 3, p77 

    Pancreatic cancer is a lethal disease because of the aggressive behavior and the most patients have been excluded from surgical resection that is the only curative treatment for pancreatic cancer at diagnosis. Therefore chemotherapy has been standard treatment for most patients with pancreatic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics